Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies Goetz, M. P., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Forrester, T., Mockbee, C., Smith, I. C., Di Leo, A., Johnston, S. AMER ASSOC CANCER RESEARCH. 2018
View details for Web of Science ID 000425489400038